Read more

September 04, 2021
2 min read
Save

Updates for AF Awareness Month: Loop monitoring, EAST-AFNET 4 and more in AF research

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

In recognition of National Atrial Fibrillation Awareness Month, Healio and Cardiology Today have aggregated some of the recent updates in AF research and treatment.

Updates include data on the arrhythmogenic effects of alcohol; the potential benefits of screening for asymptomatic AF; and the latest in AF research presented at the virtual European Society of Cardiology Congress.

Breaking News
Source: Adobe Stock

Continuous AF monitoring does not reduce risk for stroke, systemic embolism: LOOP

Continuous implantable loop recorder monitoring resulted in a threefold increase in AF detection and subsequent anticoagulation initiation, but failed to reduce risk for stroke or systemic embolism in high-risk patients. Read more

Finerenone reduces risk for new-onset AF in diabetic kidney disease

Treatment with the mineralocorticoid receptor antagonist finerenone reduced the risk for new-onset AF or flutter by 29% compared with placebo in adults with diabetic kidney disease, according to new data from the FIDELIO-DKD trial. Read more

Early rhythm control therapy for AF consistent regardless of presence of symptoms

The benefits of early, systematic rhythm control therapy were consistent regardless of whether patients had asymptomatic or symptomatic AF, according to new data from the EAST-AFNET 4 trial. Read more

Alcohol consumption raises odds of AF episode soon after in paroxysmal AF

In patients with paroxysmal AF, consumption of alcohol raises risk for an AF event shortly thereafter, according to data presented at the American College of Cardiology Scientific Session. Read more

Edoxaban ‘plausible alternative to warfarin’ to treat AF after TAVR

In the ENVISAGE-TAVI AF trial, edoxaban was noninferior to vitamin K antagonists for adverse clinical events and was associated with increased major bleeding in patients with AF who underwent transcatheter aortic valve replacement. Read more

Screening for asymptomatic AF brings potential benefits, many questions

AF accounts for 454,000 hospitalizations and 158,000 deaths annually, according to the CDC. Many with AF have symptoms, but many do not, leading to the question of whether screening in asymptomatic individuals is needed. Read more

Ablation plus CRT superior to drug therapy in patients with permanent AF, narrow QRS

Rate control with AV junction ablation plus biventricular pacing improved survival among patients with permanent AF, narrow QRS and a prior HF hospitalization compared with medical rate control therapy, a speaker reported. Read more

Cryoballoon ablation catheter now indicated as first-line treatment for AF

The FDA granted a new indication to a cryoballoon ablation catheter that allows it to be used as a first-line treatment for AF, before antiarrhythmic drugs. Read more

TEE can detect left atrial thrombus in patients with AF undergoing procedures

The prevalence of left atrial thrombus is high in certain anticoagulated patients with AF, which suggests a role for transesophageal echocardiogram imaging before procedures in that population, researchers reported. Read more